Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Sep 22;35(4):306-311.
doi: 10.4103/tcmj.tcmj_104_23. eCollection 2023 Oct-Dec.

Update in diagnosis and management of irritable bowel syndrome

Tsung-Hsing Hung  1   2 , Chih-Ying Wang  3 , Hsing-Feng Lee  1   2
Affiliations
Review

Update in diagnosis and management of irritable bowel syndrome

Tsung-Hsing Hung et al. Tzu Chi Med J. .

Abstract

Irritable bowel syndrome (IBS) is a functional gastrointestinal disorder characterized by a lack of structural or biochemical abnormalities. The current diagnosis of IBS is based on the Rome IV criteria, and it is recommended to approach IBS patients using a multidimensional clinical profile (MDCP). The pathophysiology of IBS is multifactorial and involves motility disorders, genetic factors, immune responses, visceral hypersensitivity, brain-gut dysregulation, and altered intestinal microbiota. The management of IBS includes both nonpharmacologic and pharmacologic therapies. Nonpharmacologic therapy options include physical activity, low fermentable oligosaccharides, disaccharides, monosaccharides, and polyol diet, as well as cognitive behavioral therapy. Pharmacologic therapy options include probiotics, antidepressants, antispasmodics, and new agents. In clinical practice, a multidisciplinary strategy, including nonpharmacologic or/and pharmacologic treatment for IBS, is emphasized. Therefore, clinicians should carefully consider the underlying pathophysiology before selecting an appropriate therapeutic option for the treatment of IBS. In other words, individualized treatment plans are necessary for managing IBS.

Keywords: Irritable bowel syndrome; Management; Pathophysiology.

PubMed Disclaimer

Conflict of interest statement

There are no conflicts of interest.

Figures

Figure 1
Figure 1
The biopsychosocial model of irritable bowel syndrome
See this image and copyright information in PMC

References

    1. Oka P, Parr H, Barberio B, Black CJ, Savarino EV, Ford AC. Global prevalence of irritable bowel syndrome according to Rome III or IV criteria: A systematic review and meta-analysis. Lancet Gastroenterol Hepatol. 2020;5:908–17. - PubMed
    1. Lai YT, Chen CY, Bair MJ. Epidemiology, clinical features, and prescribing patterns of irritable bowel syndrome in Taiwan. Front Pharmacol. 2021;12:788795. - PMC - PubMed
    1. Zamani M, Alizadeh-Tabari S, Zamani V. Systematic review with meta-analysis: The prevalence of anxiety and depression in patients with irritable bowel syndrome. Aliment Pharmacol Ther. 2019;50:132–43. - PubMed
    1. Trindade IA, Melchior C, Törnblom H, Simrén M. Quality of life in irritable bowel syndrome: Exploring mediating factors through structural equation modelling. J Psychosom Res. 2022;159:110809. - PubMed
    1. Cassar GE, Youssef GJ, Knowles S, Moulding R, Austin DW. Health-related quality of life in irritable bowel syndrome: A systematic review and meta-analysis. Gastroenterol Nurs. 2020;43:E102–22. - PubMed

LinkOut - more resources